Fig. 7: Survival in patients with HER2+HR− nonmetastatic IDC according to AR expression, TILs, and PD-L1.

a Kaplan–Meier curve for DFS and OS of HER2+HR− breast cancer patients with low TILs stratified by AR status. b Kaplan–Meier curve for DFS and OS of HER2+HR− breast cancer patients with PD-L1+ in tumor cells stratified by AR status. c Kaplan–Meier curve for DFS and OS of HER2+HR− breast cancer patients with PD-L1+ in immune cells stratified by AR status.